Blood 2010; 115: 3017–3024. 36 Lai GM, Chen YN, Mickley LA et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991; 49: 696–703. 37 Gutierrez M, Chabner BA, Pearson D et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: Epigenetic inhibitor ic50 3633–3642. 38 Wilson WH, Grossbard ML, Pittaluga S et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685–2693.
39 Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin’s lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071–1079. 40 Sparano JA, Wiernik PH, Hu X et al. Pilot
trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma. J Clin Oncol 1996; 14: 3026–3035. 41 Sparano JA, Lee S, Chen MG et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004; 22: 1491–1500. 42 Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens Afatinib for advanced Protirelin non-Hodgkin’s lymphoma. N Engl J Med 1993; 328: 1002–1006. 43 Linch DC, Vaughan Hudson B, Hancock BW et al. A randomised
comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin’s lymphoma: a British National Lymphoma Investigation report. Br J Cancer 1996; 74: 318–322. 44 Messori A, Vaiani M, Trippoli S et al. Survival in patients with intermediate or high grade non-Hodgkin’s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84: 303–307. 45 Miller TP, LeBlanc M, Spier C. CHOP alone compared to CHOP plus radiotherapy for early aggressive non-Hodgkin’s lymphoma: update of the SouthWest Oncology Group (SWOG) randomized trial. Blood 2001; 98: 714a. 46 Horning SJ, Weller E, Kim K et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22: 3032–3038. 47 Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007; 25: 787–792. 48 Coiffier B, Lepage E, Briere J et al.